A few of the new members Health Secretary Robert F. Kennedy Jr. appointed to the federal vaccine panel have promoted ...

BioNTech said in 2022 that it faced “threats of a groundless patent infringement suit” from a company that was “unable to ...

SK bioscience’s acquisition of German contract manufacturer IDT Biologika last year was a strategic play to globalize its ...

Shares in Hong Kong-based Regencell Bioscience Holdings nearly quadrupled in value amid a 38-to-1 stock split despite the ...

The Food and Drug Administration says it will begin offering faster reviews to new medicines that align with Trump ...

Novavax, Inc. faces profitability challenges despite a promising tech platform, with uncertain revenue streams. Click for my ...

BioNTech is acquiring CureVac in a deal that brings messenger RNA manufacturing capability and cancer immunotherapy ...

German biotech firm BioNTech has agreed to acquire domestic peer CureVac for about $1.25 billion worth of BioNTech shares, it ...

Valued at $1.25 billion, the deal expands BioNTech’s cancer drug portfolio and heads off royalty costs it could have owed ...

U.S. equities were mixed and little changed at midday as a second inflation report this week came in lower than anticipated.

CureVac shares skyrocketed 35% Thursday when the biotech firm agreed to be bought by COVID-19 vaccine maker BioNTech in an all-stock deal valued at about $1.25 billion.